Stay up to date with developments at Horizon

Cambridge, UK, 07 July 2020: Horizon Discovery Group plc today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively. The cell lines are optimized to work alongside Horizon’s Edit-R predesigned synthetic single guide RNA (sgRNA) and CRISPRa guide RNA, offering researchers a…

Cambridge 19 May 2020: Horizon Discovery and Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, have today announced the signing of a commercial license agreement which will see Horizon’s CHOSOURCE™ platform used in combination with Rentschler Biopharma’s novel in-house process for cell line development for difficult-to-express proteins

Cambridge, UK, 29 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation…